Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-hodgkin's lymphoma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 11, 2013, Pages 1632-1637

  Czajczynska, Anna ^a   Günther, Andreas ^a   Repp, Roland ^a   Humpe, Andreas ^a   Schub, Natalie ^a   Raff, Thorsten ^a   Nickelsen, Maike ^b   Schrauder, André ^a   Schrappe, Martin ^a   Kneba, Michael ^a   Gramatzki, Martin ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Advanced T cell NHL; Alemtuzumab; Allogeneic stem cell transplantation; BEAM; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CLADRIBINE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; MALE; MINIMAL RESIDUAL DISEASE; SALVAGE THERAPY; SCHOOL CHILD; T CELL LYMPHOMA; UNRELATED DONORS;

ADVANCED T CELL NHL; ALEMTUZUMAB; ALLOGENEIC STEM CELL TRANSPLANTATION; BEAM; REDUCED-INTENSITY CONDITIONING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CHILD; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL; MALE; MELPHALAN; MIDDLE AGED; REMISSION INDUCTION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84885843319     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.07.003     Document Type: Article

References (35)

1. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. JClin Oncol 2008, 26:4124-4130.
2. Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011, 117:3402-3408.
3. Coiffier B., Brousse N., Peuchmaur M., et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990, 1:45-50.
4. Arrowsmith E.R., Macon W.R., Kinney M.C., et al. Peripheral T-cell lymphomas: Clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymph 2003, 44:241-249.
5. Reimer P., Rudiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study. JClin Oncol 2009, 27:106-113.
6. Blystad A.K., Enblad G., Kvaloy S., et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001, 27:711-716.
7. Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: The Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652-657.
8. d'Amore F., Relander T., Lauritzsen G.F., et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. JClin Oncol 2012, 30:3093-3099.
9. Zain J.M., O'Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 2010, 92:33-44.
10. Enblad G., Hagberg H., Erlanson M., et al. Apilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920-2924.
11. Lundin J., Hagberg H., Repp R., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003, 101:4267-4272.
12. Dearden C.E., Matutes E., Cazin B., et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001, 98:1721-1726.
13. Kluin-Nelemans H.C., van Marwijk Kooy M., Lugtenburg P.J., et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 2011, 22:1595-1600.
14. Faulkner R.D., Craddock C., Byrne J.L., et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004, 103:428-434.
15. Gokbuget N., Stanze D., Beck J., et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2011, 120:2032-2041.
16. Schmitz N., Nickelsen M., Ziepert M., et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012, 13:1250-1259.
17. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53:457-481.
18. Schemper M., Smith T.L. Anote on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
19. Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011, 117:3402-3408.
20. Mercadal S., Briones J., Xicoy B., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958-963.
21. Nickelsen M., Ziepert M., Zeynalova S., et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: A comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009, 20:1977-1984.
22. Chen A.I., McMillan A., Negrin R.S., et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience. Biol Blood Marrow Transplant 2008, 14:741-747.
23. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. JClin Oncol 2007, 25:3109-3115.
24. Coiffier B., Pro B., Prince H.M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. JClin Oncol 2012, 30:631-636.
25. Foss F., Horwitz S.M., Coiffier B., et al. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study. Clin Lymph Myel Leuk 2012, 12:238-243.
26. Gokbuget N., Basara N., Baurmann H., et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011, 118:3504-3511.
27. d'Amore F., Radford J., Relander T., et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010, 150:565-573.
28. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
29. Kim S.W., Tanimoto T.E., Hirabayashi N., et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: A nationwide survey in Japan. Blood 2006, 108:382-389.
30. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. JClin Oncol 2008, 26:2264-2271.
31. Kyriakou C., Canals C., Finke J., et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JClin Oncol 2009, 27:3951-3958.
32. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. JClin Oncol 2004, 22:2172-2176.
33. Jacobsen E.D., Kim H.T., Ho V.T., et al. Alarge single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011, 22:1608-1613.
34. Goldberg J.D., Chou J.F., Horwitz S., et al. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymph 2012, 53:1124-1129.
35. Dodero A., Spina F., Narni F., et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: Long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012, 26:520-526.